REG - Arecor Therapeutics - ARECOR GRANTED EUROPEAN PATENTS

Arecor TherapeuticsAnnouncement

09/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220809:nRSI3281Va&default-theme=true

RNS Number : 3281V  Arecor Therapeutics PLC  09 August 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED EUROPEAN PATENTS PROTECTING PROPRIETARY FORMULATIONS OF

HIGH CONCENTRATION HUMIRA® BIOSIMILAR

 

-      Patents demonstrate strength of innovative Arestat(TM) technology
and its potential in development of enhanced formulations of high value
biologics

-      Further strengthens Group's extensive patent portfolio protecting
its proprietary Arestat™ technology and proprietary products

 

Cambridge, UK, 9 August 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the European Patent Office has granted two patents
(EP3592383B1 and EP3592385B1) protecting the Group's novel formulations of
high-concentration adalimumab until 2038.

 

Adalimumab, sold by AbbVie under the brand name Humira(®), has been a
blockbuster monoclonal antibody product since its launch in 2003, indicated
for a number of inflammatory diseases such as rheumatoid arthritis and Crohn's
disease. Global sales of Humira increased by 4% in 2021 with total sales
reported as $21bn(1).  Several biosimilar versions of adalimumab have also
entered the European market since 2018 and are due to be launched in the US in
2023.

 

Humira(®) was originally approved as a 50 mg/mL adalimumab product comprising
citrate as a key formulation ingredient. An improved product was subsequently
launched by AbbVie with a high adalimumab concentration (100 mg/mL) in the
absence of citrate, resulting in less injection site-related pain and
providing greater patient convenience due to the lower injection volumes. The
market for high-concentration adalimumab has been steadily increasing both in
the US and in Europe with high-concentration adalimumab now representing about
80% of the total US market(2).

 

Formulating a high concentration version of adalimumab is technically
challenging and further complicated by a complex patent landscape surrounding
adalimumab formulations. Using its proprietary Arestat™ technology, Arecor
has developed novel formulations enabling a high-concentration adalimumab
product (100 mg/mL or higher) with excellent stability. The two granted
European patents protect the novel design space enabling these formulations.
Corresponding patents in the US are expected to be granted later in 2022.

 

Sarah Howell, CEO of Arecor, commented: "These European patents for
high-concentration adalimumab are an important addition to Arecor's product
patent portfolio and provide further proof of the potential of our Arestat(TM)
technology in the development of enhanced biologic products, including high
value biosimilars.

 

"We have been very successful in applying the technology platform to develop
enhanced versions of existing products with key enabling features, within our
own In-house portfolio of proprietary products and with leading healthcare
companies through our technology partnerships. The biologics field is one in
which we have considerable experience, as demonstrated by the novel and
differentiated formulation of AT220, a separate biosimilar product in our
current partnered programmes, formulated by Arecor and licensed to one of our
global pharmaceutical partners, which is now in late-stage development."

 

Arecor has invested in building a strong patent portfolio to protect the
Arestat™ technology platform and its proprietary pipeline products. The
Group's intellectual property (IP) portfolio currently comprises 36 patent
families, including >50 granted patents in Europe, the US and in other key
territories.  As part of this strategy, Arecor has been developing robust IP
directed to the novel compositions of differentiated therapeutic products that
offer greater convenience of use for patients or healthcare professionals.
EP3592383B1 and EP3592385B1 represent a growing number of the Group's patents
in this area.

 

1.     AbbVie Form 10-K 2021 p41

2.
https://www.centerforbiosimilars.com/view/samsung-bioepis-and-organiz-seek-to-enter-the-market-for-high-concentration-adalimumab

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arestat™

Arecor's Arestat™ technology enables superior product profiles across a
broad range of therapies, including various types of biopharmaceuticals and
specialty hospital products. In addition to its internal portfolio of superior
proprietary products in diabetes and other indications, Arecor leverages the
Arestat™ technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their therapeutic
products under a technology licensing model.

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUWVRRUKUWRUR